Use of enadoline in the treatment of benign prostatic enlargement

A method of treating benign prostatic hypertrophy which comprises administering to a patient in need of said treatment a therapeutically effective amount of a compound in unit dosage form of the formula ##STR14## or a pharmaceutically acceptable salt thereof wherein n is an integer of from 1 to 6;

• either of X or Y is oxygen and the other is --CH.sub.2 --;
• R.sub.1 is selected from ##STR15## where R.sub.4 and R.sub.5 are independently hydrogen, fluorine, chlorine, bromine, nitro, trifluoromethyl, alkyl of from 1 to 6 carbon atoms, alkoxy of from 1 to 6 carbon atoms, or aryl;
• b) 3,4,5-trimethylphenoxy;
• ##STR16## where R.sub.6 is hydrogen, fluorine, chlorine, alkyl of from 1 to 6 carbon atoms, or aryl;
• Z is --CH.sub.2 --, --O--, --S--, or --NR.sub.7 -- where R.sub.7 is hydrogen, alkanoyl of from 1 to 6 carbon atoms, or alkyl of from 1 to 6 carbon atoms;
• ##STR17## wherein R.sub.8 and R.sub.9 are independently hydrogen, fluorine, bromine, alkyl of from 1 to 6 carbon atoms, or alkoxy of from 1 to 4 carbon atoms;
• or ##STR18## where R.sub.8 and R.sub.9 are as defined above;
• where R.sub.2 is methyl and R.sub.3 is hydrogen, alkyl of from 1 to 6 carbon atoms, ##STR19## where R.sub.10 is alkyl of from 1 to 4 carbon atoms;
• or where R.sub.2 and R.sub.3 when taken together with the nitrogen atom to which they are attached, form a pyrrolidinyl, piperidinyl, or hexahydro-1H-azepinyl ring.